Shengxiang Biology: Indications for the injection of human growth hormone expanded, approved for clinical trials.

Shengxiang Biotechnology announced that its holding subsidiary, Zhongshan Shengxiang Haiji Biopharmaceutical Co., Ltd., has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration. Its product, Recombinant Human Growth Hormone Injection, is intended to be newly applied for the indication of idiopathic short stature, and the supplementary application has been granted clinical trial approval by the National Medical Products Administration. Recombinant Human Growth Hormone Injection is a water-based injection form developed based on Shengxiang Haiji's injection form of human growth hormone. It was approved for marketing on November 7, 2023, and is used for children with slow growth due to endogenous growth hormone deficiency or short stature caused by Noonan syndrome.